JAMPRO
30.8.2021 17:02:10 CEST | Business Wire | Press release
Jamaica’s manufacturing sector has shown resilience through the COVID-19 pandemic, with the country seeing positive developments in industries such as chemicals and cosmetics.
Manufacturers have seized new opportunities to export to markets that have experienced disruptions in their supply chains. This has led to increased production of items like cleaning chemicals, sanitizers, masks, and OTC pharmaceuticals to meet local and international demand. Jamaica expects this manufacturing expansion to contribute significantly to its economic recovery effort in the next 5 years.
These developments support the island’s goal to be a manufacturing leader in the region. Its government has long highlighted the sector as an area for growth as a myriad of possibilities exist, and Jamaica is strategically located to easily access key markets like the United States, the United Kingdom, Canada, CARICOM and Latin America.
Jamaica has one of the most diverse manufacturing sectors in the Caribbean, ranging from large food-based manufacturing giants such as GraceKennedy Limited and Jamaica Producers Group , to a burgeoning “clean beauty” industry with companies like Ettenio and Irie Rock manufacturing hair and skin care for local and international consumers.
The manufacturing of medical devices, electronics, building materials, and product fitting and assembly are other activities taking place on the island. Contract manufacturing is also an emerging area, as companies seek to use the island as their manufacturing and export base. Jamaica benefits from preferential market access to several regions through trade agreements, further strengthening its position as an ideal contract manufacturing location.
Building on this strong manufacturing tradition, Jamaica’s trade and investment promotions agency, JAMPRO , says that the stage is set for more industries to grow, even with constraints created by the pandemic.
President of JAMPRO, Diane Edwards, explained, “Jamaicans are resourceful, innovative, and committed, and because of that our manufacturing sector continues to find new ways to develop products that are in demand. There are difficulties, but there are opportunities, so the government has been working to give this sector the support it needs to thrive during the pandemic.”
At JAMPRO, this assistance has included engaging manufacturers and investors to produce more value-added goods. The organisation has ongoing initiatives that deliver business-matchmaking services, and facilitates the packaging and promotion of investment projects.
In collaboration with the Jamaica Manufacturers and Exporters Association Limited (JMEA), JAMPRO also provides education and awareness around important subjects like incentives, the Special Economic Zone (SEZ) framework, and regional and global trade agreements that are favourable for products manufactured in Jamaica. The aim is to enhance opportunities for persons to do business in the island.
Positive outlook for manufacturing
With recent global trends in nearshore manufacturing and increased consumption of goods, JAMPRO envisages that more manufacturing will be taking place in Jamaica.
Global health and lifestyle trends will fuel the production of high value goods such as Jamaican Black Castor Oil and its derivatives, and cosmetics made with natural ingredients. According to Transparency Market Research (TMR) the global cosmetics ingredients market, valued at US$30 Bn in 2020, is expected to attain a market value of US$51.6 Bn by 2030.
TMR also notes the rising popularity of natural/herbal cosmetics products, as these items are viewed as healthier alternatives. This creates an excellent opportunity for Jamaica, which currently grows several of the ingredients needed to manufacture these goods.
Reflecting on these trends, Berletta Henlon Forrester, Manager of Manufacturing and Mining at JAMPRO, stated, “Entrepreneurs can explore manufacturing beyond food and beverage, and diversify into health & beauty, packaging & paper, and household chemicals. These industries are supported by Jamaica’s capacity to provide an abundance of ingredients such as bamboo, castor, turmeric, aloe vera and cannabis, to name a few .”
To produce the ideal ecosystem for the success of the aforementioned industries, Jamaica is embarking on a National Five-Year Manufacturing Growth Strategy and is executing government reforms to improve the ease of doing business. This combination should foster the growth of manufacturing and strengthen the sector’s overall performance.
Forrester said, “This is the right time for ambitious manufacturers and investors, both large and small, to initiate their strategies towards Jamaica as the location for their manufacturing project . JAMPRO will be available, as always, to provide the necessary guidance and assistance.”
ABOUT JAMPRO
The Jamaica Promotions Corporation (JAMPRO)’s mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce.
For more information on JAMPRO, please visit https://dobusinessjamaica.com/ .
Follow us on:
Twitter
Facebook
Instagram
LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005017/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
